Compare DDD & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDD | IRWD |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.1M | 578.3M |
| IPO Year | 2003 | 2009 |
| Metric | DDD | IRWD |
|---|---|---|
| Price | $1.53 | $4.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $3.50 | ★ $6.18 |
| AVG Volume (30 Days) | ★ 3.1M | 2.3M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 109.79 | N/A |
| EPS | N/A | ★ 0.91 |
| Revenue | ★ $386,902,000.00 | $298,276,000.00 |
| Revenue This Year | $1.69 | $59.19 |
| Revenue Next Year | $4.34 | $4.80 |
| P/E Ratio | ★ N/A | $5.33 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $1.64 | $2.95 |
| 52 Week High | $4.12 | $5.78 |
| Indicator | DDD | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 22.83 | 76.30 |
| Support Level | N/A | $3.90 |
| Resistance Level | $3.76 | N/A |
| Average True Range (ATR) | 0.17 | 0.24 |
| MACD | -0.10 | 0.16 |
| Stochastic Oscillator | 0.00 | 93.10 |
3D Systems Corp provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, manufacturing and applications engineering. Its solutions support applications in two key industry verticals: Healthcare Solutions provide surgical planning, implants, instrumentation, and medical education solutions to help medical device manufacturers and healthcare providers accelerate, and ultimately, transform healthcare, and Industrial Solutions which includes aerospace, defense, transportation and general manufacturing. The company operates in the Americas, EMEA, and APAC regions.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.